Home > Insider Trading > Filing (0000950170-24-041426)

Filing Details

Accession Number:: 0000950170-24-041426
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-04-03 19:33:35
Reporting Period:: 2024-04-01

Accepted Time:: 2024-04-03 19:33:35
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1745999	Beam Therapeutics Inc.	BEAM	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1786322	Giuseppe Ciaramella	C/O Beam Therapeutics Inc., 238 Main Street Cambridge MA 02142	President	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2024-04-01	4,534	$32.12	169,616	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Acquisiton	2024-04-03	27,318	$0.00	27,318	$0.67
Common Stock	Stock Option (Right to Buy)	Acquisiton	2024-04-03	12,979	$0.00	12,979	$4.22

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
27,318	2024-04-03	2028-05-08	No	4	A	Direct
12,979	2024-04-03	2029-02-13	No	4	A	Direct

Footnotes

These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on each of March 31, 2021, March 31, 2022 and March 31, 2023. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.09 to $32.18, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
On May 8, 2018, the Reporting Person was granted an option to purchase 27,318 shares of common stock of BEAM. The option vests upon BEAM achieving a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 27,318 shares.
On February 13, 2019, the Reporting Person was granted an option to purchase 12,979 shares of common stock of BEAM. The option vests upon BEAM achieving a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 12,979 shares.